Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BIIB

Biogen Inc

May 01 • 04:00PM ET

216.13

Dollar change +1.31
Percentage change 0.61	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO QQQ MOAT IVV VTV IBB VOE RSP

Index	NDX, S&P 500	P/E	27.00	EPS (ttm)	8.01	Insider Own	0.80%	Shs Outstand	144.90M	Perf Week	7.00%
Market Cap	31.47B	Forward P/E	12.36	EPS next Y	17.48	Insider Trans	-0.10%	Shs Float	144.43M	Perf Month	4.09%
Income	1.17B	PEG	8.44	EPS next Q	3.98	Inst Own	90.11%	Short Float	2.26%	Perf Quarter	-12.38%
Sales	9.29B	P/S	3.39	EPS this Y	6.28%	Inst Trans	0.83%	Short Ratio	2.51	Perf Half Y	-8.89%
Book/sh	104.48	P/B	2.07	EPS next Y	11.73%	ROA	4.56%	Short Interest	3.26M	Perf Year	-28.96%
Cash/sh	7.38	P/C	29.29	EPS next 5Y	3.20%	ROE	8.04%	52W Range	189.44 - 319.76	Perf YTD	-16.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.05%	ROI	5.32%	52W High	-32.41%	Beta	-0.01
Dividend TTM	-	Quick Ratio	1.32	Sales past 5Y	-4.53%	Gross Margin	68.31%	52W Low	14.09%	ATR (14)	5.61
Dividend Ex-Date	-	Current Ratio	2.10	EPS Y/Y TTM	-62.75%	Oper. Margin	18.67%	RSI (14)	62.22	Volatility	3.66% 2.42%
Employees	7570	Debt/Eq	0.46	Sales Y/Y TTM	-2.49%	Profit Margin	12.56%	Recom	1.58	Target Price	285.99
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	0.93%	Payout	0.00%	Rel Volume	0.71	Prev Close	214.82
Sales Surprise	-0.83%	EPS Surprise	5.78%	Sales Q/Q	-5.62%	Earnings	Apr 24 BMO	Avg Volume	1.30M	Price	216.13
SMA20	7.25%	SMA50	1.72%	SMA200	-10.94%	Trades		Volume	915,845	Change	0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300
Sep-28-22	Upgrade	Robert W. Baird	Neutral → Outperform	$224 → $340
Sep-28-22	Upgrade	Mizuho	Neutral → Buy	$207 → $270
Sep-28-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$217 → $360
Apr-18-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$235 → $265
Mar-08-22	Downgrade	Stifel	Buy → Hold	$304 → $223
Mar-03-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$227 → $248
Feb-04-22	Reiterated	Wolfe Research	Peer Perform	$244 → $217

Show Previous Ratings

Apr-30-24 11:15AM	Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts? (Investor's Business Daily)
Apr-29-24 10:03AM	7 Retirement Stocks to Buy at a 52-Week Low in April (InvestorPlace)
09:50AM	10 Most Promising Stocks to Buy Before They Take Off (Insider Monkey)
Apr-26-24 11:27AM	Guggenheim Adjusts Price Target on Biogen to $255 From $275 (MT Newswires)
05:00AM	Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup (Quartz)
01:02AM	Loading…
01:02AM	Decoding Biogen Inc (BIIB): A Strategic SWOT Insight (GuruFocus.com)
Apr-25-24 04:05PM	Biogen Receives Positive CHMP Opinion for TOFIDENCE (tocilizumab), a Biosimilar Referencing ROACTEMRA (GlobeNewswire)
02:15PM	Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	For Beaten-Down Maker of Alzheimers Drug, Good Enough Will Do (The Wall Street Journal)
01:23AM	Q1 2024 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-24-24 06:18PM	Why Biogen Stock Leaped Nearly 5% Higher Today (Motley Fool)
04:19PM	Biogen Stock Surges After Two Notable Products Walloped Sales Expectations (Investor's Business Daily)
04:01PM	Analyst Report: Biogen Inc. (Morningstar Research)
02:12PM	Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings (Benzinga)
12:57PM	Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake (Zacks)
12:45PM	Loading…
12:45PM	Biogen (BIIB) Q1 2024 Earnings Call Transcript (Motley Fool)
12:28PM	Biogen: Dont expect any big acquisitions this year (BioPharma Dive)
11:53AM	BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:13AM	Biogen shares rise on sales of groundbreaking Alzheimer's drug Leqembi (Quartz)
11:08AM	Biogen Stock Rises After Earnings, Jump in Sales of Alzheimers Drug (Barrons.com)
10:39AM	To be better at neuroscience, Biogen will invest outside the therapeutic area (FierceBiotech.com)
10:28AM	Biogen stock rises on Q1 results, Alzheimer's drug sales (Yahoo Finance Video)
10:05AM	Biogen Affirms Guidance After Mixed First Quarter (MT Newswires)
09:39AM	Alzheimers Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock (The Wall Street Journal)
09:34AM	Biogen Beats Estimates as Alzheimers Drug Gains Traction (Bloomberg)
09:30AM	Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:00AM	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday (MT Newswires)
08:39AM	Alzheimers Drug Leqembi Finally Sees Sales Pickup (The Wall Street Journal)
08:32AM	Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts (GuruFocus.com)
07:45AM	Biogen's Q1 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Adjusted Earnings Guidance, Shares Gain 4% Pre-Bell (MT Newswires)
07:15AM	Loading…
07:15AM	Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook (RTT News)
06:48AM	Biogen cost cuts drive profit beat, Alzheimer's drug sales jump (Reuters)
06:45AM	Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? (Investor's Business Daily)
06:45AM	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump (Reuters)
Apr-23-24 12:23AM	Should You Be Confident in Biogen (BIIB)? (Insider Monkey)
Apr-19-24 09:39AM	What's in Store for Biogen (BIIB) This Earnings Season? (Zacks)
09:15AM	Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Apr-17-24 10:01AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-12-24 10:00AM	Biogen Is Suffering From Doubts About the Future (GuruFocus.com)
Apr-11-24 02:15PM	Is Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision? (Investor's Business Daily)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
Apr-01-24 05:50PM	Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
04:02PM	Software Acquisition Group Inc. III (NASDAQ:SWAG) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-31-24 07:30PM	Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA (PR Newswire)
11:53AM	12 Best S&P 500 Stocks To Buy According to Analysts (Insider Monkey)
Mar-28-24 08:00AM	Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback (Investor's Business Daily)
Mar-27-24 12:18PM	Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-26-24 11:21AM	CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug (Zacks)
Mar-25-24 05:50PM	Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know (Zacks)
Mar-22-24 07:05AM	UPDATE 3-EU regulator delays decision on Eisai-Biogen Alzheimer's drug (Reuters)
06:57AM	EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes (Reuters)
Mar-21-24 05:14PM	Hedge Funds and Insiders Are Buying These 10 Stocks (Insider Monkey)
09:17AM	Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside (Barrons.com)
04:39AM	Biogen, Moderna, and 6 More Healthcare Stocks With Room to Grow (Barrons.com)
Mar-18-24 05:50PM	Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today (Zacks)
10:16AM	25 Most Stressed Cities in the United States (Insider Monkey)
Mar-15-24 09:34AM	Biogen's CMO Maha Radhakrishnan departs, leaving behind a legacy in Alzheimer's drug development (FierceBiotech.com)
Mar-14-24 11:30AM	Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report? (Zacks)
Mar-12-24 05:50PM	Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
09:00AM	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions (Business Wire)
Mar-08-24 04:11PM	FDA delays approval deadline for Eli Lilly's Alzheimer's drug (Yahoo Finance Video)
04:07PM	Three-Stock Lunch: Biogen, DocuSign (CNBC TV)
02:48PM	Top Stock Movers Now: Broadcom, Costco, MongoDB, and More (Investopedia)
02:38PM	Eli Lilly's Alzheimer's Drug Release Delayed for FDA Investigation (Investopedia)
11:44AM	FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug (Associated Press Finance)
10:58AM	Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision (Benzinga)
10:52AM	Eli Lilly Alzheimers Drug Delayed as FDA Plans Advisory Panel Meeting (The Wall Street Journal)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
Mar-07-24 09:31AM	Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline (FierceBiotech.com)
Mar-06-24 05:45PM	Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know (Zacks)
07:30AM	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy (GlobeNewswire)
Mar-05-24 05:50PM	Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market (Zacks)
08:33AM	After tough rightsizing, Biogen looks to newer rare diseases to broaden lens (FierceBiotech.com)
Mar-04-24 04:15PM	Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD ) 2024 Annual Meeting (GlobeNewswire)
Mar-02-24 04:53AM	1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223? (Motley Fool)
Mar-01-24 01:45PM	Is Eli Lilly Stock A Buy On Projection For $81 Billion In Weight-Loss Sales? (Investor's Business Daily)
Feb-28-24 05:45PM	Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market (Zacks)
Feb-25-24 07:04AM	14 Best Beaten Down Stocks To Buy Right Now (Insider Monkey)
Feb-23-24 12:44PM	Is Eli Lilly Stock A Buy As Amgen Enters The Red-Hot Weight-Loss Ring? (Investor's Business Daily)
07:00AM	Biogen's QALSODY (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP (GlobeNewswire)
06:14AM	UPDATE 2-EU medicines regulator backs Biogen's ALS drug (Reuters)
05:56AM	EU medicines regulator backs Biogen's ALS drug (Reuters)
Feb-20-24 11:21AM	20 Most Sustainable Companies in the US (Insider Monkey)
Feb-19-24 01:46PM	From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 (InvestorPlace)
Feb-15-24 04:13PM	7 Contrarian Biotech Stocks to Consider Amid Sector Weakness (InvestorPlace)
Feb-14-24 05:11PM	Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says (Benzinga)
09:11AM	Biogen Inc. (NASDAQ:BIIB) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:42AM	Sage offers details on launch of new postpartum depression pill (BioPharma Dive)
06:37AM	UPDATE 2-Biogen gets DOJ subpoena on business operations in foreign countries (Reuters)
06:18AM	Biogen receives subpoena from DOJ on business operations in foreign countries (Reuters)
01:35AM	Q4 2023 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-13-24 04:34PM	Analyst Report: Biogen Inc. (Morningstar Research) -7.39%
02:45PM	Biogen (BIIB) Q4 2023 Earnings Call Transcript (Motley Fool)
01:09PM	PRIMECAP Management Bolsters Stake in Biogen Inc (GuruFocus.com)
12:53PM	Biogen Plunges as Alzheimer Drugs Slow Uptake Signals Reset (Bloomberg)
11:44AM	Biogen Tumbles as Drug Closeout Costs, Multiple Sclerosis Medicine Sales Weigh on Profit (Investopedia)
11:17AM	Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls (Zacks)
10:50AM	Biogen Promised a Return to Growth. Why the Stock Is Dropping. (Barrons.com)
10:44AM	Biogen, Molson Coors, Krispy Kreme: Trending tickers (Yahoo Finance Video)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 08 '24	Option Exercise	0.00	2,335	0	15,063	Feb 09 08:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 08 '24	Option Exercise	0.00	2,101	0	7,895	Feb 09 08:01 PM
Kramer Robin	Chief Accounting Officer	Feb 08 '24	Option Exercise	0.00	788	0	4,943	Feb 09 08:06 PM
Gregory Ginger	EVP, Human Resources	Feb 08 '24	Option Exercise	0.00	1,635	0	10,118	Feb 09 08:14 PM
Izzar Rachid	Head of Global Product Strat.	Feb 08 '24	Option Exercise	0.00	2,043	0	8,187	Feb 09 08:11 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 08 '24	Option Exercise	0.00	2,190	0	48,101	Feb 09 08:16 PM
Singhal Priya	Head of Development	Feb 02 '24	Sale	245.93	634	155,920	4,097	Feb 05 06:38 PM
Singhal Priya	Head of Development	Feb 01 '24	Option Exercise	0.00	1,828	0	5,292	Feb 05 06:38 PM
Singhal Priya	Head of Development	Dec 11 '23	Sale	248.00	110	27,280	3,464	Dec 12 05:06 PM
Kramer Robin	Chief Accounting Officer	Dec 08 '23	Option Exercise	0.00	351	0	4,325	Dec 12 05:02 PM
Singhal Priya	Head of Development	Dec 08 '23	Option Exercise	0.00	426	0	3,780	Dec 12 05:06 PM
BIOGEN INC.	10% Owner	Sep 26 '23	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM
Singhal Priya	Head of Development	Sep 05 '23	Sale	269.43	431	116,124	3,354	Sep 06 06:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01 '23	Option Exercise	0.00	5,285	0	14,060	Sep 06 06:08 PM
Singhal Priya	Head of Development	Sep 01 '23	Option Exercise	0.00	1,668	0	4,592	Sep 06 06:06 PM
Singhal Priya	Head of Development	Jul 03 '23	Sale	282.87	81	22,912	2,924	Jul 05 05:33 PM
Singhal Priya	Head of Development	Jun 30 '23	Option Exercise	0.00	315	0	3,158	Jul 05 05:33 PM
Izzar Rachid	Head of Global Product Strat.	Jun 30 '23	Option Exercise	0.00	504	0	6,388	Jul 05 05:37 PM
Kramer Robin	Chief Accounting Officer	Jun 30 '23	Option Exercise	0.00	252	0	4,096	Jul 05 05:35 PM

Open in Screener

VSTM

Verastem Inc

May 01 • 04:00PM ET

9.98

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC

Index	-	P/E	-	EPS (ttm)	-4.08	Insider Own	19.05%	Shs Outstand	25.28M	Perf Week	7.20%
Market Cap	252.49M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	-0.41%	Shs Float	20.48M	Perf Month	-13.37%
Income	-87.37M	PEG	-	EPS next Q	-1.03	Inst Own	47.84%	Short Float	3.94%	Perf Quarter	-15.06%
Sales	0.00M	P/S	-	EPS this Y	5.09%	Inst Trans	-	Short Ratio	5.74	Perf Half Y	60.45%
Book/sh	2.27	P/B	4.40	EPS next Y	26.95%	ROA	-71.39%	Short Interest	0.81M	Perf Year	89.02%
Cash/sh	5.46	P/C	1.83	EPS next 5Y	1.74%	ROE	-138.76%	52W Range	4.68 - 15.18	Perf YTD	22.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-73.33%	52W High	-34.26%	Beta	0.58
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	-45.06%	Gross Margin	-	52W Low	113.25%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	5.45	EPS Y/Y TTM	11.24%	Oper. Margin	0.00%	RSI (14)	41.59	Volatility	4.44% 5.49%
Employees	73	Debt/Eq	0.53	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	28.79
Option/Short	Yes / Yes	LT Debt/Eq	0.52	EPS Q/Q	-3.51%	Payout	-	Rel Volume	0.65	Prev Close	9.98
Sales Surprise	-100.00%	EPS Surprise	-66.83%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	140.53K	Price	9.98
SMA20	-6.09%	SMA50	-12.47%	SMA200	3.88%	Trades		Volume	91,195	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Loading…
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
04:00PM	Loading…
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire)
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:30PM	Loading…
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire)
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire)
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)
05:45PM	Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jan-18-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-11-23 06:24AM	individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week (Simply Wall St.) +11.00%
Dec-15-22 04:30PM	Verastem Oncology Appoints Rob Gagnon to Board of Directors (Business Wire) -5.00%
Nov-08-22 08:22AM	Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) (Simply Wall St.)
Nov-03-22 04:05PM	Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-20-22 07:00AM	Verastem Oncology Appoints Anil Kapur to Board of Directors (Business Wire)
Oct-07-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.49%
Oct-04-22 07:00AM	Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates (Business Wire) -34.60%
Sep-19-22 09:31AM	10 Long-Term Stocks to Buy During Recessions (Insider Monkey)
Aug-23-22 12:23PM	Investors five-year losses grow to 64% as the stock sheds US$34m this past week (Simply Wall St.)
Aug-08-22 07:00AM	Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) +7.56%
Jul-27-22 11:40AM	Is Verastem (NASDAQ:VSTM) Using Too Much Debt? (Simply Wall St.)
Jul-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Jun-27-22 11:17AM	What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition (Simply Wall St.)
Jun-07-22 02:26PM	RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm (Benzinga) +11.07%
Jun-06-22 07:00AM	Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer (Business Wire) -8.27%
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now (InvestorPlace) +5.13%
May-18-22 08:45AM	Verastem Oncology Awarded Pancreatic Cancer Action Networks First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer (Business Wire)
May-09-22 04:05PM	Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) -9.52%
08:25AM	Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-04-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99%
Mar-28-22 01:46PM	Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development (Benzinga) +10.92%
07:05AM	Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
07:00AM	Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors (Business Wire)
Mar-24-22 07:05AM	Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board (Business Wire)
Mar-01-22 07:52AM	Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates (Zacks)
Feb-22-22 05:00AM	Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago (Simply Wall St.)
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com) -7.59%
Jan-11-22 07:00AM	Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire)
Jan-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 04:05PM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Nov-23-21 08:53AM	Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC (Zacks)
Nov-22-21 07:30AM	Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer (PR Newswire)
Nov-15-21 06:01AM	10 Best Biotech Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 (Insider Monkey)
Nov-11-21 07:00AM	Verastem Oncology to Present at the Jefferies London Healthcare Conference (Business Wire) +10.57%
Nov-04-21 04:05PM	Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
09:25AM	11 Best Long-Term Stocks To Buy Now (Insider Monkey)
Oct-26-21 07:00AM	Verastem Oncology Appoints Michelle Robertson to Board of Directors (Business Wire)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Gagnon Robert E.	Director	Feb 06 '24	Sale	13.70	9,204	126,095	27,804	Feb 07 04:00 PM
Gagnon Robert E.	Director	Jan 12 '24	Sale	10.95	9,204	100,784	37,008	Jan 17 04:00 PM
Calkins Daniel	Chief Financial Officer	Jan 05 '24	Sale	8.50	6	51	8,621	Jan 09 04:03 PM
Calkins Daniel	Chief Financial Officer	Dec 26 '23	Sale	8.08	25	202	8,350	Dec 28 04:04 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '23	Sale	7.93	57	452	8,375	Dec 21 04:01 PM
Stuglik Brian M	Director	Dec 19 '23	Sale	7.73	274	2,118	90,450	Dec 20 04:00 PM
Paterson Dan	President and CEO	Dec 19 '23	Sale	7.73	183	1,415	86,916	Dec 20 04:01 PM
Gagnon Robert E.	Director	Dec 19 '23	Sale	7.73	130	1,005	46,212	Dec 20 04:03 PM
Stuglik Brian M	Director	Dec 18 '23	Sale	7.64	487	3,721	90,724	Dec 20 04:00 PM
Gagnon Robert E.	Director	Dec 18 '23	Sale	7.64	284	2,170	46,342	Dec 20 04:03 PM
Paterson Dan	President and CEO	Dec 18 '23	Sale	7.64	244	1,864	87,099	Dec 20 04:01 PM
Calkins Daniel	Vice President of Finance	Oct 05 '23	Sale	7.30	5	36	8,432	Oct 10 04:31 PM
Calkins Daniel	Vice President of Finance	Sep 25 '23	Sale	9.40	25	235	8,437	Sep 25 04:46 PM
Calkins Daniel	Vice President of Finance	Sep 21 '23	Sale	9.31	232	2,160	8,462	Sep 25 04:46 PM
Stuglik Brian M	Director	Sep 19 '23	Sale	9.84	274	2,696	91,211	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 19 '23	Sale	9.84	183	1,801	87,343	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 19 '23	Sale	9.84	130	1,279	46,626	Sep 20 04:15 PM
Stuglik Brian M	Director	Sep 18 '23	Sale	9.91	478	4,737	91,485	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 18 '23	Sale	9.91	278	2,755	46,756	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 18 '23	Sale	9.91	240	2,378	87,526	Sep 20 04:15 PM
Calkins Daniel	Vice President of Finance	Jul 06 '23	Sale	8.02	5	40	8,694	Jul 10 04:05 PM
Calkins Daniel	Vice President of Finance	Jun 26 '23	Sale	8.17	26	212	8,422	Jun 28 04:11 PM
Stuglik Brian M	Chief Executive Officer	Jun 20 '23	Sale	10.30	275	2,832	91,963	Jun 21 04:23 PM
Paterson Dan	President and COO	Jun 20 '23	Sale	10.30	183	1,885	37,766	Jun 21 04:25 PM
Gagnon Robert E.	Director	Jun 20 '23	Sale	10.30	130	1,339	47,034	Jun 21 04:24 PM
Stuglik Brian M	Chief Executive Officer	Jun 16 '23	Sale	9.92	487	4,831	92,238	Jun 21 04:23 PM
Gagnon Robert E.	Director	Jun 16 '23	Sale	9.92	283	2,807	47,164	Jun 21 04:24 PM
Paterson Dan	President and COO	Jun 16 '23	Sale	9.92	244	2,420	37,949	Jun 21 04:25 PM

Open in Screener

FBIO

Fortress Biotech Inc

May 01 • 04:00PM ET

1.74

Dollar change +0.07
Percentage change 4.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

FBIO Fortress Biotech Inc daily Stock Chart

Held by: VTI VXF FESM

Index	-	P/E	-	EPS (ttm)	-21.66	Insider Own	28.32%	Shs Outstand	15.09M	Perf Week	-2.79%
Market Cap	33.46M	Forward P/E	-	EPS next Y	-4.68	Insider Trans	47.93%	Shs Float	13.79M	Perf Month	-9.84%
Income	-66.66M	PEG	-	EPS next Q	-1.73	Inst Own	24.35%	Short Float	13.21%	Perf Quarter	-14.71%
Sales	84.51M	P/S	0.40	EPS this Y	29.40%	Inst Trans	-13.18%	Short Ratio	6.38	Perf Half Y	2.35%
Book/sh	1.49	P/B	1.17	EPS next Y	21.68%	ROA	-26.26%	Short Interest	1.82M	Perf Year	-85.18%
Cash/sh	4.21	P/C	0.41	EPS next 5Y	25.50%	ROE	-188.71%	52W Range	1.24 - 11.85	Perf YTD	-42.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.28%	ROI	-65.56%	52W High	-85.32%	Beta	1.55
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	26.66%	Gross Margin	66.41%	52W Low	40.32%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	-57.11%	Oper. Margin	-164.76%	RSI (14)	43.54	Volatility	5.52% 6.67%
Employees	186	Debt/Eq	3.93	Sales Y/Y TTM	11.58%	Profit Margin	-78.88%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	3.51	EPS Q/Q	79.56%	Payout	-	Rel Volume	0.40	Prev Close	1.67
Sales Surprise	31.94%	EPS Surprise	52.58%	Sales Q/Q	21.59%	Earnings	Mar 28 AMC	Avg Volume	285.61K	Price	1.74
SMA20	-3.52%	SMA50	-8.86%	SMA200	-49.26%	Trades		Volume	112,944	Change	4.19%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Today 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire)
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire)
12:24PM	Loading…
Apr-11-24 12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Mar-28-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.83%
04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-22-24 08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-21-24 04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
08:30AM	Loading…
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire) +15.18%
08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire) -5.45%
Mar-12-24 08:30AM	Fortress Biotech to Participate in 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) -6.55%
Mar-04-24 08:30AM	Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease (GlobeNewswire) -5.76%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Feb-02-24 02:40PM	Lindsay Rosenwalds Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries (News Direct) -6.09%
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
05:02PM	Loading…
Jan-09-24 05:02PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ... (GuruFocus.com) -6.19%
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire)
08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
Jan-03-24 04:01PM	Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.81%
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -10.63%
08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-29-23 08:20AM	Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.62%
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com)
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire) -9.95%
Aug-14-23 04:19PM	Fortress Biotech: Q2 Earnings Snapshot (AP Finance)
04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-23 04:01PM	Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:30AM	Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Aug-02-23 04:01PM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:54PM	Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77m (Simply Wall St.)
08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) -16.57%
Jul-19-23 08:30AM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 (GlobeNewswire)
Jul-11-23 08:30AM	Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults (GlobeNewswire)
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.04%
Jul-05-23 02:31PM	Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit (Simply Wall St.)
Jul-03-23 08:00AM	Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States (GlobeNewswire) +7.55%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire) -5.69%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.55%
08:00AM	Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program (GlobeNewswire)
Jun-13-23 08:30AM	Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects (GlobeNewswire)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jan 05 '24	Buy	2.38	50,000	118,770	2,863,905	Jan 09 08:15 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14 '23	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14 '23	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26 '23	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18 '23	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17 '23	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience